Actively Recruiting
Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis
Led by Psoriasis Treatment Center of Central New Jersey · Updated on 2019-02-04
30
Participants Needed
1
Research Sites
47 weeks
Total Duration
On this page
Sponsors
P
Psoriasis Treatment Center of Central New Jersey
Lead Sponsor
L
LEO Pharma
Collaborating Sponsor
AI-Summary
What this Trial Is About
4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks
CONDITIONS
Official Title
Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female adult 63 18 years of age
- Diagnosis of chronic plaque-type psoriasis
- Psoriasis affecting 2-10% of body surface area
- Physician Global Assessment score of 2 or greater
- Treated with etanercept or adalimumab for at least 24 weeks
You will not qualify if you...
- Body surface area affected less than 2% or greater than 10%
- Physician Global Assessment score less than 2
- Not currently receiving etanercept or adalimumab, or treated with these for less than 24 weeks
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Psoriasis Treatment Center of Central New Jersey
East Windsor, New Jersey, United States, 08520
Actively Recruiting
Research Team
J
Jerry Bagel, MD
CONTACT
E
Elise Nelson
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here